The Model for End-Stage Liver Disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy

Cancer

Volumn 107, Issue 1, 2006, Pages 141-148

  Huo, Teh Ia ^a,b   Lin, Han Chieh ^a,b   Huang, Yi Hsiang ^a,b   Wu, Jaw Ching ^a,b   Chiang, Jen Huei ^a,b   Lee, Pui Ching ^b   Lee, Shou Dong ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cancer of Liver Italian Program; Child Turcotte Pugh; Cirrhosis; Hepatocellular carcinoma; Japan Integrated Scoring; Model for End Stage Liver Disease

Indexed keywords

ACETIC ACID; ALCOHOL; ALPHA FETOPROTEIN; BILIRUBIN; CREATININE; GELFOAM; IOPROMIDE;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CANCER MORTALITY; CANCER OF LIVER ITALIAN PROGRAM SYSTEM; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD TURCOTTE PUGH SYSTEM; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLUOROSCOPY; FOLLOW UP; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INJECTION; INTERNATIONAL NORMALIZED RATIO; JAPAN INTEGRATED SCORING SYSTEM; LIVER ANGIOGRAPHY; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; ITALY; JAPAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745320148     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21972     Document Type: Article

References (40)

1. El-Serag HB, Davila JA. Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
2. Hussain SA, Perry DR, El-Gazzaz G, et al Hepatocellular carcinoma. Ann Oncol. 2001;12:101-172.
3. Marrero JA. Fontana RJ. Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-715.
4. Huo TI, Lee SD, Wu JC. Staging for hepatocellular carcinoma: look for a perfect classification system. J Hepatol. 2004;40:1041-1042.
5. Huo TI, Huang YH. Staging for hepatocellular carcinoma: treatment strategy matters. Hepatology. 2005;41:678.
6. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840-845.
7. Di Bisceglie AM, Strasberg S. A common staging system for hepatocellular carcinoma. Hepatology. 2004;39:550-551.
8. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-1405.
9. Toyoda H, Kumada T, Kiriyama S, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol. 2005;100:1764-1771.
10. Wiesner R, Edwards E, Freeman R, et al. The United Network for Organ Sharing Liver Disease Severity Score Committee. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.
11. Freeman RB, Wiesner RH, Roberts JP, et al. Improving liver allocation: MELD and PELD. Am J Transplant. 2004;4(Suppl 9):114-131.
12. Olthoff KM, Brown RS Jr., Delmonico FL, et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. Liver Transpl. 2004; 10(10 Suppl 2):A6-A22.
13. Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003;52:134-139.
14. Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36:494-500.
15. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421-430.
16. Testa R, Testa E, Giannini E, et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-Stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569.
17. Befeler AS, Palmer DE, Hoffman M, et al. The safety of intra-abdominal surgery in patients with cirrhosis: Model for End-Stage Liver Disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg. 2005;140:650-654.
18. Huo TI, Huang YH, Wu JC, et al. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol. 2003;38:770-778.
19. Huo TI, Huang YH, Wu JC, et al. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. Aliment Pharmacol Ther. 2004;19:1391-1398.
20. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
21. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
22. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997;16:965-980.
23. Feinsten AR. Clinical biostatistics XVI. The process of prognostic stratification. Clin Pharmacol Ther. 1972;13:609-624.
24. Foster MR. Key concepts in model selection: performance and generalizability. J Math Psychol. 2000;44:205-231.
25. Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40:897-903.
26. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353-358.
27. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant. 2005;5:307-313.
28. Freeman RB. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: evidence-based patient selection. Liver Transpl. 2004; 10(10 Suppl 2):S2-S3.
29. Angermayr B, Cejna M, Karnel F, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52:879-885.
30. Farnsworth N, Fagan SP, Berger DH, et al. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg. 2004;188:580-583.
31. Northup PG, Wanamaker RC, Lee VD, et al. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg. 2005;242:244-251.
32. Huo TI, Wu JC, Lui WY, et al. Reliability of contemporary radiology to measure tumor size of hepatocellular carcinoma in patients undergoing resection: limitations and clinical implications. Scand J Gastroenterol. 2004;39:46-52.
33. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
34. Greene FL, Page DL, Fleming ID, et al., editors. The AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
35. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol. 2004;40:124-131.
36. Toyoda H, Kumada T, Kiriyama S, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol. 2005;100:1764-1771.
37. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760-1769.
38. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
39. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2003;97:1042-1050.
40. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(Suppl 1):S100-S107.